Impotence News and Research

RSS

Erectile dysfunction, sometimes called "impotence," is the repeated inability to get or keep an erection firm enough for sexual intercourse. The word "impotence" may also be used to describe other problems that interfere with sexual intercourse and reproduction, such as lack of sexual desire and problems with ejaculation or orgasm. Using the term erectile dysfunction makes it clear that those other problems are not involved.

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Nymox Pharmaceutical Corporation outlined today the Company's development program for the Company's lead drug candidate, NX-1207, currently in Phase 3 trials in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.

31 Mar 2010

Abbott's sNDA for new six-month 45-mg formulation of Lupron Depot: FDA accepts for review

The U.S. Food and Drug Administration has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer. Palliative treatment helps to relieve symptoms associated with advanced prostate cancer.

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

Accurate, life-saving diagnostic tools needed for screening and prevention of prostate cancer, says AdMeTech

AdMeTech President and CEO Dr. Faina Shtern told the U.S. House Committee on Oversight and Government Reform that a major national commitment is needed to create accurate, life-saving diagnostic tools for prostate cancer and end what she called "the prostate cancer crisis."

4 Mar 2010

AdMeTech Foundation: Health care reform highlights need for better screening and prevention of prostate cancer

AdMeTech Foundation announced today that its President and CEO Dr. Faina Shtern will testify on March 4 before the U.S. House Committee on Oversight and Government Reform on how health care reform highlights the need for increased funding for research aimed at creating accurate, life-saving diagnostic tools for prostate cancer, which will improve screening, prevention, early detection and reduce health costs.

2 Mar 2010

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

US HIFU, a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device, has announced its intention to fund a landmark multi-center trial to study focal therapy for localized prostate cancer. Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH), along with Hashim Uddin Ahmed, MRC clinical research fellow, will lead the trial.

25 Feb 2010

Majority of long-term cancer survivors do not have access to personalized care services

An increasing number of people are surviving cancer, but many do not receive the services and support they need in the long term, Macmillan Cancer Support has said.

8 Jan 2010

BioMarin Pharmaceutical receives marketing approval for amifampridine phosphate

BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing approval for 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

6 Jan 2010

Androgen receptor plays critical role in wound healing

A molecular receptor pivotal to the action of male hormones such as testosterone also plays a crucial role in the body's ability to heal, report scientists in the December issue of the Journal of Clinical Investigation.

5 Jan 2010

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously received orphan drug designation in the E.U.

30 Nov 2009

Pfizer’s Revatio Injection receives FDA approval

Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.

20 Nov 2009

Cancer screening methods are not perfect: Experts

In a recent New York Times article, the American Cancer Society (ACS) ignited a major controversy over the benefits of cancer screening, specifically with regards to their breast and prostate cancer guidelines. In the article, Dr. Otis Brawley, chief medical officer of the ACS, responded to a study in the current issue of the Journal of the American Medical Association.

11 Nov 2009

Elevated PSA levels in men are not necessarily a predictor of the need for a prostate biopsy: Study

Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.

7 Nov 2009

Health Canada approves the Zenith Branch Endovascular Graft-Iliac Bifurcation

Canadian physicians can now treat patients suffering from life-threatening aneurysms in one of the body’s largest arteries with an endovascular graft delivered during a minimally invasive procedure without blocking a critical artery.

4 Nov 2009

Adenosine deaminase enzyme therapy offers hope for priapism

For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope. That's because researchers from the United States and China show that the enzyme adenosine deaminase may prevent priapism from progressing to penile fibrosis, a condition associated with the build up of scar tissue and eventual impotence.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

MIRP surgery carries higher risk of impotence and incontinence than traditional surgery

A new study debating the effectiveness of minimally invasive prostate surgery is not telling the whole story, warns Dr. David B. Samadi, Chief of the Division of Robotics and Minimally Invasive Surgery in the Department of Urology at The Mount Sinai Medical Center in New York.

21 Oct 2009

Vanda Pharmaceuticals announces its agreement with Novartis Pharma AG

Vanda Pharmaceuticals Inc. announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults.

14 Oct 2009

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Accuray Incorporated, a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery.

1 Oct 2009